Quest Diagnostics Incorporated (DGX) has been garnering significant attention from investors and analysts alike. The company has received a consensus recommendation as a Moderate Buy and has recently declared a quarterly cash dividend of $0.71. The company has received praise as a Best Place for Disability Inclusion and manages to exhibit strong performance on trading days.
The company's acquisitions of
LifeLabs and Lab Assets from OhioHealth also highlight its aim to extend the accessibility of diagnostic innovation, with aims to acquire Outreach Laboratory Services further reinforcing this agenda. Also notable is the development of tests for H5 Avian Influenza and Oropouche Virus, under contracts awarded by the CDC.
Financially, Quest Diagnostics has reported sturdy financial results for both Q2 & Q3 2024 and enhanced their guidance for FY 2024. Moreover, the company sees a substantial rise in stock as backed by strong revenue growth. Collaborations such as the one with
BD to develop companion diagnostics for cancer, amongst other diseases, underscore the company's innovative potential.
Quest Diagnostics DGX News Analytics from Tue, 09 Jan 2024 08:00:00 GMT to Sat, 09 Nov 2024 08:23:13 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 3
